financetom
Business
financetom
/
Business
/
Blueport Acquisition Ltd Announces Closing of $57.5 Million Initial Public Offering, Including Full Exercise of Underwriters' Over-Allotment Option
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Blueport Acquisition Ltd Announces Closing of $57.5 Million Initial Public Offering, Including Full Exercise of Underwriters' Over-Allotment Option
Nov 13, 2025 1:41 PM

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Blueport Acquisition Ltd, a blank check company incorporated in the Cayman Islands as an exempted company (the “Company”), today announced the closing of its previously announced initial public offering (“IPO”) of 5,750,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one right to receive one-sixth (1/6) of one Class A ordinary share upon the consummation of an initial business combination. This includes the exercise in full by the underwriters' over-allotment option to purchase up to an additional 750,000 units.

The units are listed on The Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “BPACU” and began trading on November 12, 2025. Once the securities comprising the units begin separate trading, the Class A ordinary shares and the rights are expected to be traded on Nasdaq under the symbols “BPAC” and “BPACR,” respectively.

A.G.P./Alliance Global Partners acted as the sole book-running manager for the offering.

Loeb & Loeb LLP served as legal counsel to the Company and McDermott Will & Schulte LLP served as legal counsel to A.G.P./Alliance Global Partners in the offering.

A registration statement on Form S-1 relating to the securities was previously filed with the Securities and Exchange Commission ("SEC") and became automatically effective on November 10, 2025 pursuant to Section 8(a) of the Securities Act of 1933, as amended. This offering was made only by means of a prospectus forming part of the effective registration statement. Copies of the final prospectus, may be obtained on the SEC’s website at http://www.sec.gov. Electronic copies of the final prospectus, may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Blueport Acquisition Ltd

The Company is a blank check company incorporated in the Cayman Islands as an exempted company with limited liability for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The Company intends to conduct a search for target businesses without being limited by a particular industry. The Company is led by Mr. William Rosenstadt, the Company’s Chief Executive Officer, and Mr. Kulwant Sandher, the Company’s Chief Financial Officer.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the IPO and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the IPO filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Image: https://www.globenewswire.com/newsroom/ti?nf=OTU3NTYxMiM3MjYzODI4IzUwMDE1NDczMw==

Image: https://ml.globenewswire.com/media/ZmUxMzQyYWMtMzA0Mi00OTk1LWE1MGEtY2MzNzYyNGZkZDY3LTUwMDE1NDczMy0yMDI1LTExLTEzLWVu/tiny/Blueport-Acquisition.png

Source: Blueport Acquisition

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Orca Energy Group to Cease SS-7 Well Intervention Operations
Orca Energy Group to Cease SS-7 Well Intervention Operations
Dec 19, 2024
10:41 AM EST, 12/19/2024 (MT Newswires) -- Orca Energy Group (ORC-B.V, ORC-A.V) overnight Wednesday said it and affiliates had ceased well intervention operations and begun demobilization of the barge and jackup from the SS-7 site, on Songo Songo Island, Tanzania. The company had attempted to produce gas from the southern compartment of the gas field. Following successful water shut off...
Olive Garden Parent Darden Raises Full-Year Revenue Outlook as Fiscal Second-Quarter Results Top Views
Olive Garden Parent Darden Raises Full-Year Revenue Outlook as Fiscal Second-Quarter Results Top Views
Dec 19, 2024
10:41 AM EST, 12/19/2024 (MT Newswires) -- Darden Restaurants ( DRI ) lifted its full-year revenue outlook on Thursday as the restaurant operator recorded better-than-expected fiscal second-quarter results. The parent company of Olive Garden ( DRI ) and LongHorn Steakhouse now anticipates revenue of about $12.1 billion for fiscal 2025, up from its previous projections of $11.8 billion to $11.9...
Ocugen Secures Data and Safety Monitoring Board Approval to Advance OCU410 Trial for Geographic Atrophy
Ocugen Secures Data and Safety Monitoring Board Approval to Advance OCU410 Trial for Geographic Atrophy
Dec 19, 2024
10:39 AM EST, 12/19/2024 (MT Newswires) -- Ocugen ( OCGN ) said Thursday the Data and Safety Monitoring Board approved the continuation of its phase 1/2 trial for OCU410, a gene therapy for geographic atrophy secondary to dry age-related macular degeneration. Initial phase 2 data showed OCU410 is safe and well-tolerated, with no serious adverse events reported, the company said....
Adaptimmune Therapeutics Chief Financial Officer Gavin Wood to Resign in May 2025
Adaptimmune Therapeutics Chief Financial Officer Gavin Wood to Resign in May 2025
Dec 19, 2024
10:40 AM EST, 12/19/2024 (MT Newswires) -- Adaptimmune Therapeutics ( ADAP ) said Thursday that Gavin Wood will step down as chief financial officer on May 31, 2025. The biopharmaceutical company said co-founder Helen Tayton-Martin will also resign as chief business and strategy officer on March 31. Price: 0.59, Change: -0.01, Percent Change: -2.31 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved